Companies with clinical development experience are constantly trolling for compounds they can in-license to leverage those capabilities, but the market for quality compounds is tight.

InterMune Pharmaceuticals Inc. last week put a twist on this search by leveraging its ongoing clinical development program for Actimmune interferon gamma-Ib to obtain access to profits from IFN gamma sales in markets owned by Boehringer Ingelheim GmbH. ITMN will take over responsibility for clinical and regulatory development in Boehringer's markets in exchange for a portion of profits.